A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 659-665

  Hirsch, Martin ^a   Steigbigel, Roy ^b   Staszewski, Scholomo ^c   Mellors, John ^d   Scerpella, Ernesto ^f   Hirschel, Bernard ^f   Lange, Joep ^f   Squires, Kathleen ^f   Rawlins, Sandy ^e   Meibohm, Anne ^e   Leavitt, Randi ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Merck and Co Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; PLACEBO; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; SURVIVAL RATE; ZIDOVUDINE;

EID: 0032883118     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314948     Document Type: Article

References (12)

1. 1. Hammer SM, Squire KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
2. 2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
3. 3. Gulick R, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection 100-week follow-up. JAMA 1998; 280:35-41.
4. 4. Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis 1998; 177:1514-20.
5. 5. Dawson JD, Lagakos SW. Analyzing laboratory marker changes in AIDS clinical trials. J Acquir Immune Defic Syndr 1991; 4:667-76.
6. 6. Dawson JD. Comparing treatment groups on the basis of slopes, areas-under-the curve, and other summary measures. Drug Information J 1994; 28: 723-32.
7. 7. Liang KY, Zeger SL. Longitudinal data analysis using generalised linear models. Biometrika 1986; 73:13-22.
8. 3. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1998:383.
9. 9. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-I infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-24.
10. 10. US package circular. Crixivan®. West Point, PA: Merck, February 1998.
11. 11. Steigbigel R, Cooper D, Clumeck N, Ghosh K, Nguyen BY, Merck Protocol 037 Study Group. Indinavir with stavudine vs. IDV alone vs. stavudine alone in zidovudine experienced, HIV-infected patients. In: Conference Record 12th World AIDS Conference, Geneva, Switzerland, June 28 July 3, 1998:12335.
12. 12. Robertson M, Nessly M, Aversa D, Leavitt R. Changes in serum cholesterol and triglyceride levels in patients treated with indinavir or NRTIs. In: 6th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1999:648.